Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3

Cervical Intraepithelial Neoplasia 3 Clinical Trial

— CIN3  

Official title:

A Single Center, Open-label, Dose-escalating, Phase Ι Study to Evaluate the Safety of GX-188E Administered by Electroporation (EP) in DNA-based Therapeutic Vaccine for Patients With Cervical Intraepithelial Neoplasia Grade 3 (CIN 3)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01634503
• Other study ID #: GX-188E-SN
• Status: Completed
• Phase: Phase 1
• First received: July 3, 2012
• Last updated: February 14, 2014
• Start date: November 2012
• Est. completion date: February 2014

Study information

• Verified date: February 2014
• Source: Genexine, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Ministry of Food and Drug Safety
• Study type: Interventional

Clinical Trial Summary

This study is to determine maximum tolerable dose (MTD) of GX 188E by defining the safety profile the safety and maximum tolerated dose of GX-188E administered by electroporation in Cervical Intraepithelial Neoplasia grade 3 (CIN 3) patients.

Description:

This study is an open-label, dose-escalation, single-center, phase I study to evaluate the safety of GX-188E, a DNA-based therapeutic vaccine, administered by electroporation (EP) in patients with HPV-16 or HPV-18 associated cervical intraepithelial neoplasia grade 3 (CIN 3).

Each subject eligible to participate in the trial is given a subject number, which is assigned sequentially in ascending order, then allocated to only a single dose level of the drug. Three subjects are allocated at each dose level starting with 1mg whereby the dose is escalated in sequential subjects in ascending numerical order of subject ID.

Each subject visit the site three times for administration during the study and is given an intramuscular injection of GX-188E at a dose of 1mg, 2mg or 4mg by electroporation at each visit

The subjects conduct the follow-up visits twice, which are 8 weeks and 24 weeks after the third injection of GX-188E respectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: February 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Female aged between 20 and 50(inclusive).

• Those who promised not to get pregnant from initiation to the first follow-up visit

• Who has diagnosed with Cervical Intraepithelial Neoplasia 3 by histopathologic examination and HPV type 16 or 18 detected

• Those who signed a voluntary written informed consent form for study participation.

Exclusion Criteria:

• Pregnant or lactating women.

• Administration of immunosuppressant or immunomodulator within 6 months prior to the enrollment

• Concomitant medication of any corticosteroid agents within 4 weeks prior to vaccination with the test drug

• Prior immunotherapy against HPV

• Administration of any blood products within 3 months prior to the screening visit

• Administration of any vaccine within 4 weeks prior to the screening visit (ex. Hepatitis A vaccine, Hepatitis B vaccine, Influenza vaccine, Td etc.)

• Positive serum test results for hepatitis C virus, hepatitis B virus surface antigen(HBsAg), or HIV

• Prior participation in any clinical trial within 30 days prior to the screening visit

• Patients predisposed to inflammatory reaction due to use of medical devices such as electroporation within 30 days of screening visit

• Past history of epilepsy or convulsion within 2 years prior to the screening visit

• At the discretion of the investigator, the skin condition covering deltoid muscles, within 2cm of the intended sites of injection, is not suitable for injection due to infection, ulcer, edema, tattoo, scar, injury etc.

• The thickness of skin fold covering deltoid muscles, intended injection sites, >40mm

• Any orthopedic artificial implant around the intended sites of electroporation (deltoid muscles)

• Any history of severe adverse drug events or severe allergic diseases

• Sinus bradycardia whose resting heart rate < 50beats/min.

• Pre-excitation syndrome such as Wolff-Parkinson-White syndrome

• Artificial implants or metallic implants

• Abnormal electrocardiography (ECG) including arrhythmia

• Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma in Situ
• Cervical Intraepithelial Neoplasia
• Cervical Intraepithelial Neoplasia 3
• Neoplasms

Intervention

Genetic:
• GX-188E administered by electroporation
Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.

Locations

Country	Name	City	State
Korea, Republic of	Cheil General Hospital & Women's Healthcare Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Genexine, Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of maximum MTD by defining the safety profile of GX-188E	It would be determined based on the rate and severity grade of events or abnormalities through evaluating systemic or local adverse events, clinical laboratory test results, vital signs and so on.	From baseline to end of study	Yes
Secondary	The expression levels of GX-188E in blood		At week -2, week 2, week 12 ,week 20 and week 36	No
Secondary	Immunologic reactogenicity by measuring HPV E6 and E7 specific T cell response (IFN-? ELISPOT)		At week -2, week 2, week 12 ,week 20 and week 36	No
Secondary	The changes of the involved lesions and HPV infection status		Baseline, week 12 ,week 20 and week 36	No